MedTrace Logo

Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments

NCT00976222 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-09-29

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).

Conditions

  • Pigment Epithelial Detachment

Interventions

DRUG

intravitreal injection with ranibizumab

0.5 mg in 0.05 ml, monthly, 12 months

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Nicole Eter, MD · Dept. of Ophthalmology, University of Muenster Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2014-12-31
Completion
2015-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00976222 on ClinicalTrials.gov